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COST-EFFECTIVENESS ANALYSIS OF THE FIXED COMBINED
ORAL TREATMENT WITH TRAMADOL/ACETAMINOPHEN
(TRAMACET®) FOR THE MANAGEMENT OF LOWER 
BACK PAIN AT THE IMSS (MEXICAN INSTITUTE OF 
SOCIAL SECURITY)
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1Janssen-Cilag, Mexico, Mexico, Mexico, 2Janssen Cilag, Ciudad De
México, México D. F, Mexico
OBJECTIVES: To assess the cost-effectiveness of a ﬁxed combi-
nation of Tramadol and Acetaminophen (Tramacet*) for the
management of Lower Back Pain (LBP) in Mexico. The eco-
nomic evaluation was performed from a Mexican Institute of
Social Security (IMSS), health service hospital perspective.
METHODS: A cost-effectiveness analysis was developed with a
decision model. The cost-effectiveness ratio for the therapeutic
use of the ﬁxed combination of Tramadol and acetaminophen
(Tramacet*) compared to treatment with Piroxicam, Celecoxib
and Diclofenac was estimated. One thousand of patients hospi-
talized in 2004 at the IMSS with LBP crisss were retrospectively
included. This sample was used as a pattern for analyzing each
alternative. A decision tree was developed based on the treat-
ment of the disorder within the national health care system, and
the cost for each node was determined. The costs of drug therapy,
family medicine ambulatory consultations, clinical specialty con-
sultations, rehabilitation, emergency care and hospitalization
were included. Labor productivity and disability rates were also
considered. Costs sources were obtained from the ofﬁcial and
published ﬁnancial and costs reports of IMSS. RESULTS: Tra-
macet leads to an increase in the number of patients with posi-
tive response to the treatment. Therapy with Tramacet had an
annual cost of $28,640 pesos (2603.63 USD), and had the lowest
hospitalization cost of all the alternatives. Also, Tramacet leads
to savings for $2769 pesos (251.72 USD), compared to conven-
tional treatment, and $648 pesos (58.90 USD) compared to
Piroxicam; additionally, for every percentage point of increased
improvement in the quality of life, Tramacet leads to savings of
$374 pesos(34 USD). CONCLUSION: This study demonstrated
that Tramacet is a cost-efﬁcient and dominant alternative for the
management of patients with chronic to acute LBP.
PPN6
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OBJECTIVES: There are two forms of injectable IV diclofenac
available (bolus and infusion). We conducted a cost minimiza-
tion analysis to determine the total cost of each treatment strat-
egy. METHODS: A decision-analytic model was developed to
estimate total treatment costs of IV bolus versus IV infusion
diclofenac. The modeled population was patients who post-
operatively would require injectable NSAIDs to control their
pain. The model timeframe was for the duration that a patient
required post-operative pain management with injectable med-
ication. The model inputs included the cost of medicines
(NSAIDs and rescue medication), the cost of the IV administra-
tion process (staff time and consumables), and the cost of treat-
ing adverse events (staff time, medicines and consumables). The
unit costs and resources are based on UK data. The results are
expressed as Pounds Sterling and as average cost per patient.
One-way sensitivity analyses were also conducted on key para-
meters. RESULTS: The total cost of treating post-operative pain
was less with IV bolus diclofenac than with IV infusion
diclofenac. Diclofenac IV bolus cost a mean GPB26.72 per
patient overall versus diclofenac IV infusion mean cost of
GPB77.18 per patient. The difference in overall cost is attribut-
able to the cost of NSAIDs (IV bolus GPB11.43 versus GPB1.69
IV Infusion), the cost of administering the NSAIDs (IV bolus
GPB9.00 versus GPB48.28 IV Infusion) and the cost of con-
sumables (IV bolus GPB1.38 versus GPB16.70 IV infusion). The
difference in the costs of rescue medication (IV bolus GPB2.80
versus GPB6.14 IV infusion) and of treating adverse events (IV
bolus GPB2.11 versus GPB4.37 IV infusion) was less. One-way
sensitivity analyses show the results are sensitive to the cost of
staff time and consumables. CONCLUSION: Diclofenac IV
bolus is cost saving relative to diclofenac IV infusion in the treat-
ment of post-operative pain.
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THE SPECTRUM OF HEALTH CARE COSTS ASSOCIATED
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POSTHERPETIC NEURALGIA
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OBJECTIVES: To estimate the burden of illness (BOI) of herpes
zoster (HZ) pain and postherpetic neuralgia (PHN) in a com-
mercially insured, Medicare, and Medicaid populations.
METHODS: Health care expenditures attributable to HZ acute
pain and postherpetic neuralgia (PHN) were calculated using
Thomson-Medstat’s databases for inpatient, outpatient, and out-
patient prescription claims. Patient cohorts were deﬁned as those
with a diagnosis of PHN, those with a diagnosis of HZ and less
than 30 days of analgesic use, and those with a diagnosis of HZ
and more then 30 days of analgesic use. For each of these
cohorts, a random sample of patients without HZ or PHN was
selected and propensity score matched based on patient demo-
graphics and overall comorbidities. Expenditures between
PHN/HZ cohorts and matched control cohorts were compared
to derive the BOI attributable to each condition. This was done
separately for commercially insured, Medicaid, and Medicare
patients. RESULTS: Patients without a diagnosis of PHN were
much more common in the sample than were patients diagnosed
with PHN. The average cost per patient in the year following a
diagnosis of HZ and less than 30 days of analgesic use ranged
from $757 to $1313, depending on type of insurance. The
average cost associated with a diagnosis of PHN or with a diag-
nosis of HZ followed by greater than 30 days of analgesic use
but no diagnosis of PHN were similar and ranged from $2159
to $5742. CONCLUSION: Health care costs associated with
PHN were substantially greater than those associated with HZ
pain that resolved within 30 days. Because patients with a diag-
nosis of HZ and persisting analgesic use (but no diagnosis of
PHN) accounted for the majority of the total expenditures,
future research must consider the impact of under-diagnosis on
estimates of the health costs associated with both HZ and PHN.
PPN8
OUT-OF-POCKET PRICES OF OPIOID ANALGESICS IN THE
UNITED STATES
Craig BM1, Strassels SA2
1University of Wisconsin, Madison, WI, USA, 2University of Texas at
Austin College of Pharmacy, Austin,TX, USA
OBJECTIVES: Pain is one of the most common reasons that
patients seek medical care, yet little information is available
about the out-of-pocket costs of pain management. Economic
burden is of particular interest in the United States, because drug
prices are allowed to ﬂuctuate freely across time, region, and
